Lymphangioma medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(4 intermediate revisions by 3 users not shown)
Line 1: Line 1:


__NOTOC__
__NOTOC__
Line 5: Line 4:
{{CMG}} {{AE}} {{Badria}} {{HL}}
{{CMG}} {{AE}} {{Badria}} {{HL}}
==Overview==
==Overview==
* There is no particular medical treatment for [[lymphangioma]]; the mainstay of therapy is surgery.  
* There is no particular medical treatment for [[lymphangioma|lymphangioma]]. The mainstay of therapy is surgery.  


==Medical Therapy==
==Medical Therapy==
There is no particular medical treatment for [[lymphangioma]]; the mainstay of therapy is surgery.
There is no particular medical treatment for [[lymphangioma]]. The mainstay of therapy is surgery:
* However [[propranolol]] is a potential option, which can be used in intractable [[lymphangiomatosis]].<ref name="pmid1533">{{cite journal |vauthors=Sack M, Cassidy JT, Bole GG, Vinar O |title=Prognostic factors in polyarteritis |journal=J. Rheumatol. |volume=2 |issue=4 |pages=411–20 |date=December 1975 |pmid=1533 |doi= |url=}}</ref>  
* However, [[propranolol]] is a potential option, which can be used in intractable [[lymphangiomatosis]].<ref name="pmid1533">{{cite journal |vauthors=Sack M, Cassidy JT, Bole GG, Vinar O |title=Prognostic factors in polyarteritis |journal=J. Rheumatol. |volume=2 |issue=4 |pages=411–20 |date=December 1975 |pmid=1533 |doi= |url=}}</ref>  
* [[Sodium tetradecyl sulfate]] is an off lable option for treatment of [[lymphangioma circumscriptum]].<ref name="pmid1524">{{cite journal |vauthors=Moos F, Richard P, Sugiura M, Iwasaki K, Kato R |title=[Adrenergic and cholinergic control of oxytocin release evoked by vaginal, vagal and mammary stimulation in lactating rats (author's transl)] |language=French |journal=J. Physiol. (Paris) |volume=70 |issue=3 |pages=315–32 |date=November 1975 |pmid=1524 |doi= |url=}}</ref>
* [[Sodium tetradecyl sulfate]] is an off-label option for treatment of [[lymphangioma circumscriptum]].<ref name="pmid1524">{{cite journal |vauthors=Moos F, Richard P, Sugiura M, Iwasaki K, Kato R |title=[Adrenergic and cholinergic control of oxytocin release evoked by vaginal, vagal and mammary stimulation in lactating rats (author's transl)] |language=French |journal=J. Physiol. (Paris) |volume=70 |issue=3 |pages=315–32 |date=November 1975 |pmid=1524 |doi= |url=}}</ref>
 
===== Other Therapies include:<ref name="pmid5556746">{{cite journal |vauthors=Rajasingham R, Bell JL, Baron DN |title=A comparative study of the isoenzymes of mammalian alpha-amylase |journal=Enzyme |volume=12 |issue=2 |pages=180–6 |date=1971 |pmid=5556746 |doi= |url=}}</ref> =====
*Destructive treatments with [[Carbon dioxide|carbon dioxide (CO2)]] [[laser]]
*Long-pulsed Nd-YAG [[laser]]


* [[Electrosurgery]]  
Other therapies include:<ref name="pmid5556746">{{cite journal |vauthors=Rajasingham R, Bell JL, Baron DN |title=A comparative study of the isoenzymes of mammalian alpha-amylase |journal=Enzyme |volume=12 |issue=2 |pages=180–6 |date=1971 |pmid=5556746 |doi= |url=}}</ref>
* Destructive treatments with [[Carbon dioxide|carbon dioxide (CO2)]] [[laser]]
* Long-pulsed Nd-YAG [[laser]]
* [[Electrosurgery]]
* [[Cryotherapy]]
* [[Cryotherapy]]
* Superficial [[radiotherapy]] [[sclerotherapy]] with 23.4% [[hypertonic]] [[saline]]  
* Superficial [[radiotherapy]] [[sclerotherapy]] with 23.4% [[hypertonic]] [[saline]]
* Direct injection of a sclerosing agent, including 1% or 3% [[sodium tetradecyl sulfate]], [[doxycycline]] or [[ethanol]]
* Direct injection of a sclerosing agent, including 1% or 3% [[sodium tetradecyl sulfate]], [[doxycycline]] or [[ethanol]]



Latest revision as of 04:42, 10 February 2019


Lymphangioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lymphangioma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lymphangioma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphangioma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphangioma medical therapy

CDC on Lymphangioma medical therapy

Lymphangioma medical therapy in the news

Blogs on Lymphangioma medical therapy

Directions to Hospitals Treating Lymphangioma

Risk calculators and risk factors for Lymphangioma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Badria Munir M.B.B.S.[2] Haytham Allaham, M.D. [3]

Overview

  • There is no particular medical treatment for lymphangioma. The mainstay of therapy is surgery.

Medical Therapy

There is no particular medical treatment for lymphangioma. The mainstay of therapy is surgery:

Other therapies include:[3]

References

  1. Sack M, Cassidy JT, Bole GG, Vinar O (December 1975). "Prognostic factors in polyarteritis". J. Rheumatol. 2 (4): 411–20. PMID 1533.
  2. Moos F, Richard P, Sugiura M, Iwasaki K, Kato R (November 1975). "[Adrenergic and cholinergic control of oxytocin release evoked by vaginal, vagal and mammary stimulation in lactating rats (author's transl)]". J. Physiol. (Paris) (in French). 70 (3): 315–32. PMID 1524.
  3. Rajasingham R, Bell JL, Baron DN (1971). "A comparative study of the isoenzymes of mammalian alpha-amylase". Enzyme. 12 (2): 180–6. PMID 5556746.


Template:WikiDoc Sources